Volume 21 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(12): 2022-2026
CHEN Xiaoshuang, GAO Zhengjie, GAO Panke, XING Rui, HAN Xiaolin, LI Jingdong. Relationship between LMR, PNI and chemotherapy response and prognosis in patients with multiple myeloma[J]. Chinese Journal of General Practice, 2023, 21(12): 2022-2026. doi: 10.16766/j.cnki.issn.1674-4152.003281
Citation: CHEN Xiaoshuang, GAO Zhengjie, GAO Panke, XING Rui, HAN Xiaolin, LI Jingdong. Relationship between LMR, PNI and chemotherapy response and prognosis in patients with multiple myeloma[J]. Chinese Journal of General Practice, 2023, 21(12): 2022-2026. doi: 10.16766/j.cnki.issn.1674-4152.003281
shu

Relationship between LMR, PNI and chemotherapy response and prognosis in patients with multiple myeloma

doi: 10.16766/j.cnki.issn.1674-4152.003281
  • 1.

    Department of Hematology, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, China

Funds:

 LHGJ20210523

  • Received Date: 2023-08-07
    Abstract
  •   Objective  To investigate the effects of lymphocyte-monocyte ratio (LMR) and prognostic nutritional index (PNI) with chemotherapy response and prognosis in patients with multiple myeloma (MM).  Methods  A total of 243 MM patients admitted to the First Affiliated Hospital of Xinxiang Medical University from March 2016 to May 2022 were selected. LMR and PNI were calculated. According to the median, patients were divided into PNI group (< 47.2, 121 cases) and high PNI group (≥47.2, 122 cases), high LMR group (≥5.85, 123 cases) and low LMR group (< 5.85, 120 cases). The clinical data, chemotherapy efficacy and prognosis of patients in different groups were compared, and subgroup analysis of patients receiving bortezomib was performed.  Results  There was no significant difference in the efficacy of chemotherapy between the high PNI group and the low PNI group (P>0.05), and there was no significant difference in the efficacy of chemotherapy between the low LMR group and the high LMR group (P>0.05). After 1 to 92 months of follow-up, 110 patients died and 133 patients survived. The median OS of the low PNI group was shorter than that of the PNI group (31 months vs. 39 months, χ2=4.130, P < 0.05), and the median OS of the low LMR group was shorter than that of the high LMR group (31 months vs. 41 months, χ2= 10.308, P < 0.01). Among 136 patients who received bortezomib-based chemotherapy, there was no significant difference in median OS between the low and high PNI groups (30 months vs. 36 months, χ2=2.814, P>0.05). The median OS of the low LMR group was shorter than that of the LMR group (30 months vs. not reached, χ2=7.618, P < 0.05). Cox regression analysis showed that low PNI and low LMR were independent risk factors for OS.  Conclusion  PNI and LMR can be used as simple and reliable prognostic indicators for MM patients. PNI and LMR can identify high-risk patients early, but cannot predict response to chemotherapy.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    GOLDSCHMIDT H. Clinical update-multiple myeloma[J]. Radiologe, 2022, 62(1): 3-11. doi: 10.1007/s00117-021-00941-0
    [2]
    CARDONA-BENAVIDES I J, DE RAMÓN C, GUTIÉRREZ N C. Genetic abnormalities in multiple myeloma: prognostic and therapeutic Implications[J]. Cells, 2021, 10(2): 336. doi: 10.3390/cells10020336
    [3]
    SUZUKI K, NISHIWAKI K, NAGAO R, et al. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis[J]. Int J Hematol, 2021, 114(5): 599-607. doi: 10.1007/s12185-021-03201-y
    [4]
    WEI M, GUO H, LIU S, et al. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era[J]. Medicine (Baltimore), 2021, 100(41): e27521. DOI: 10.1097/MD.0000000000027521.
    [5]
    CHEN L, BAI P, KONG X, et al. Prognostic nutritional index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator[J]. Front Cell Dev Biol, 2021, 9: 656741. DOI: 10.3389/fcell.2021.656741.
    [6]
    LI W, QU Y, WEN F, et al. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases[J]. Biomark Med, 2021, 15(13): 1071-1084. doi: 10.2217/bmm-2020-0786
    [7]
    MOZAS P, RIVERO A, RIVAS-DELGADO A, et al. The prognostic nutritional index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma[J]. Leuk Lymphoma, 2022, 63(4): 903-910. doi: 10.1080/10428194.2021.2010064
    [8]
    MA S, ZHANG B, LU T, et al. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study of the Huaihai Lymphoma Working Group[J]. Cancer, 2022, 128(19): 3487-3494. doi: 10.1002/cncr.34405
    [9]
    VINCENT RAJKUMAR S. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2014, 89(10): 999-1009.
    [10]
    HARI P N, ZHANG M J, ROY V, et al. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant[J]. Leukemia, 2009, 23(8): 1528-1534. doi: 10.1038/leu.2009.61
    [11]
    ZHOU F, GUO L. Lncrna ANGPTL1-3 and its target microRNA-30a exhibit potency as biomarkers for bortezomib response and prognosis in multiple myeloma patients[J]. Hematology, 2022, 27(1): 596-602. doi: 10.1080/16078454.2022.2072062
    [12]
    XIANG Y, XU X, YANG B, et al. Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients[J]. Ir J Med Sci, 2022, 191(2): 671-679. doi: 10.1007/s11845-021-02586-3
    [13]
    邹瑞基, 邹忠晴, 熊艳秋, 等. 调节性免疫细胞在多发性骨髓瘤中的临床价值研究进展[J]. 中国肿瘤临床, 2022, 49(20): 1033-1038. doi: 10.12354/j.issn.1000-8179.2022.20211647

    ZOU R J, ZOU Z Q, XIONG Y Q, et al. Research progress on clinical value of regulatory immune cells in multiple myeloma[J]. Chinese Journal of Clinical Oncology, 2022, 49(20): 1033-1038. doi: 10.12354/j.issn.1000-8179.2022.20211647
    [14]
    BELTRAN B E, CASTRO D, DE LA CRUZ-VARGAS J A, et al. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma[J]. Br J Haematol, 2019, 184(4): 650-653. doi: 10.1111/bjh.15141
    [15]
    徐翼, 纪沛君, 刘兴元, 等. CCL2通过抑制CD8+T细胞活性促进NSCLC肿瘤生长[J]. 免疫学杂志, 2022, 38(7): 597-604.

    XU Y, JI P J, LIU X Y, et al. CCL2 promotes NSCLC tumor growth by inhibiting CD8+ T cell activity[J]. Immunological Journal, 2022, 38(7): 597-604.
    [16]
    ZHANG X, DUAN J, WEN Z, et al. Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and meta-analysis[J]. Front Oncol, 2021, 11: 766672. DOI: 10.3389/fonc.2021.766672.
    [17]
    彭千涯, 马瑞娟, 郭睿娜, 等. 淋巴细胞/单核细胞比率与校正血钙作为新诊断多发性骨髓瘤预后标志物的意义[J]. 中国实验血液学杂志, 2022, 30(1): 152-157.

    PENG Q Y, MA R J, GUO R N, et al. Significance of lymphocyte-to-monocyte ratio and corrected levels of serum calcium as prognostic markers in patients with newly diagnosed multiple myeloma[J]. Journal of Experimental Hematology, 2022, 30(1): 152-157.
    [18]
    YAN D, SHEN Z, ZHANG S, et al. Prognostic values of geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI) in elderly patients with Diffuse Large B-Cell Lymphoma[J]. J Cancer, 2021, 12(23): 7010-7017. doi: 10.7150/jca.62340
    [19]
    梁飞, 董雪燕, 唐国峰, 等. 预后营养指数、控制营养状况对多发性骨髓瘤患者预后的影响[J]. 中华血液学杂志, 2021, 42(4): 332-337.

    LIANG F, DONG X Y, TANG G F, et al. Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma[J]. Chinese Journal of Hematology, 2021, 42(4): 332-337.
    [20]
    苏传勇, 陶叠宏, 任莉, 等. 多发性骨髓瘤患者外周血NLR水平与T淋巴细胞亚群的相关性及对预后的影响[J]. 中华全科医学, 2022, 20(2): 209-211, 232. doi: 10.16766/j.cnki.issn.1674-4152.002314

    SU C Y, TAO D H, REN L, et al. Correlation between peripheral blood neutrophil to lymphocyte ratio level and T lymphocyte subsets in patients with multiple myeloma and its impact on prognosis[J]. Chinese Journal of General Practice, 2022, 20(2): 209-211, 232. doi: 10.16766/j.cnki.issn.1674-4152.002314
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (220) PDF downloads(14) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return